UBS Group Issues Positive Forecast for Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Stock Price

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLXGet Free Report) had its target price upped by equities research analysts at UBS Group from $21.00 to $22.00 in a research note issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. UBS Group’s price target would suggest a potential upside of 21.48% from the stock’s previous close.

Separately, William Blair upgraded Telix Pharmaceuticals Limited American Depositary Shares to a “strong-buy” rating in a report on Tuesday, November 19th.

View Our Latest Research Report on Telix Pharmaceuticals Limited American Depositary Shares

Telix Pharmaceuticals Limited American Depositary Shares Stock Up 0.6 %

NASDAQ:TLX opened at $18.11 on Monday. Telix Pharmaceuticals Limited American Depositary Shares has a 12-month low of $14.01 and a 12-month high of $19.99. The company has a fifty day moving average of $15.93.

About Telix Pharmaceuticals Limited American Depositary Shares

(Get Free Report)

Telix Pharmaceuticals Limited is a biopharmaceutical company which focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It involved in developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases.

Further Reading

Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.